Use of platelet activating factor acetylhydrolase as a biomarker for anaphylaxis
US8562982B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Sep 3, 2012 |
| Grant date | Oct 22, 2013 |
| Priority date | — |
| Expiry date | Sep 3, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a use of platelet activating factor acetylhydrolase (PAF-AH) activity as a biomarker for severe or fatal anaphylaxis in a subject. The level of PAF-AH activity inversely correlates with the susceptibility to severe or fatal anaphylaxis. The use comprises assaying PAF-AH activity in a sample from the subject and comparing the measured activity to a reference value, wherein a lower level of measured PAF-AH activity relative to said reference level of PAF-AH activity indicates a presence of or susceptibility to severe or fatal anaphylaxis in the subject. A method for treating or preventing severe or fatal anaphylaxis in a subject is also provided. The method comprises increasing serum platelet activating factor acetylhydrolase (PAF-AH) concentration in the subject by administering to the subject, PAF-AH and/or a PAF receptor antagonist. A composition for treating severe or fatal anaphylaxis is also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.